Aplastic anemia is not considered a terminal disease and belongs to the category of benign diseases of the blood system, but some patients, such as patients with severe aplastic anemia, have poor treatment efficacy, which may lead to a shorter survival period. 1. Aplastic anemia is a kind of hematological disease characterized by bone marrow hematopoietic failure. Immunosuppressive treatment, i.e. intravenous injection of anti-human thymocyte globulin, etc., can be preferred; testosterone undecanoate and cyclosporine A can also be taken orally for treatment; bone marrow hematopoietic stem cell transplantation is also feasible. After treatment through the above methods, most of the patients can restore the hematopoietic function of bone marrow to varying degrees, so as to meet the physiological needs of the human body, and even some patients can be completely cured. Therefore, aplastic anemia is not a terminal disease. 2. However, some patients with aplastic anemia have difficulty in recovering the hematopoietic function of the bone marrow after active treatment, and may suffer from serious anemia, infection and bleeding and other complications, such as severe lung infection, intracranial hemorrhage, etc., which are life-threatening, and are commonly found in elderly patients with aplastic anemia of advanced age and patients with severe aplastic anemia. It is recommended that patients with aplastic anemia should consult the Department of Hematology in a timely manner, and individualized treatment plans should be formulated by specialists after assessing their conditions, and supportive treatments such as blood transfusion, platelet transfusion, and anti-infection (levofloxacin) should be provided.